2022
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
Phung M, Webb P, DeFazio A, Fereday S, Lee A, Bowtell D, Fasching P, Goode E, Goodman M, Karlan B, Lester J, Matsuo K, Modugno F, Brenton J, Van Gorp T, Pharoah P, Schildkraut J, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, Deurloo C, Terry K, Hanley G, Pike M, Berchuck A, Ramus S, Pearce C, Consortium O. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecologic Oncology 2022, 168: 68-75. PMID: 36401943, PMCID: PMC10398872, DOI: 10.1016/j.ygyno.2022.10.018.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerEstrogen-only therapyPrimary cytoreductive surgeryMacroscopic residual diseaseResidual diseaseParous womenFamily history of ovarian cancerOvarian Cancer Association ConsortiumMenopausal hormone therapy useHistory of ovarian cancerFirst-degree family historyCytoreductive surgeryOvarian cancer riskOvarian cancerAdvanced stage high-grade serous ovarian cancerPresence of macroscopic residual diseaseHormone therapy useHigh-grade serous ovarian cancer patientsDepot medroxyprogesterone acetate useBody mass indexLogistic regression modelsOral contraceptive useIncomplete pregnanciesSerous ovarian cancerFactors influencing survival
2020
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Consortium F. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology 2020, 158: 702-709. PMID: 32641237, PMCID: PMC7487048, DOI: 10.1016/j.ygyno.2020.06.481.Peer-Reviewed Original ResearchConceptsMenopausal hormone therapyOvarian cancer survivalMHT useResidual diseaseHormone therapyCancer survivalOvarian cancerHigh-grade serous carcinomaMacroscopic residual diseaseHormone therapy useFavorable prognostic factorPost-menopausal womenOvarian Cancer Association ConsortiumProportional hazards modelRecency of useImproved survivalPrognostic factorsTherapy useSerous carcinomaOvarian carcinomaHazards modelSmall studyAdvanced stageLarger studyLogistic regression